Imagine a global weather map, but instead of storms, it tracks how viruses change and spread. By following groups of people across 19 countries, researchers can spot new mutations before they become huge problems. This helps them figure out if current vaccines still work or if we need a new recipe to stay protected.
Vaccine and treatment effectiveness drops as viruses mutate, leaving healthcare providers and pharma companies reacting to variants rather than predicting them.
A genome analysis pipeline, an in silico model for predicting virus evolution, a secure global data warehouse, and an AI tool for predicting long COVID.
If you are a vaccine manufacturer dealing with rapidly mutating viruses — this project developed a phenotypic landscape map that identifies how new variants evade immunity. This allows for faster updates to vaccine formulas based on real-world data from 19 countries.
If you are a diagnostics company dealing with tests that fail to detect new mutations — this project developed a genome analysis pipeline and surveillance schemes. This ensures your diagnostic tools remain accurate as the virus evolves.
If you are an AI developer dealing with the complexity of chronic post-viral symptoms — this project developed an artificial intelligence driven tool for the prediction of long COVID. This can be integrated into patient monitoring software to improve long-term care.
Based on available project data, no pricing or cost structures are mentioned as this is a Horizon-RIA funded research project.
The project uses a global network across 19 countries and a secure data warehouse, suggesting the infrastructure can handle large-scale international data, though industrial manufacturing scale is not detailed.
Based on available project data, specific licensing terms are not provided; however, the project involves 25 partners including universities and research centers.
The project is active from 2022-05-01 and is scheduled to conclude by 2025-10-31.
The project integrates with WHO and existing cohort partners to ensure preparedness and response through harmonized data collection and a shared code repository.
The consortium is heavily weighted toward academic and public research, consisting of 7 universities and 10 research organizations. With 0% industry participation and 0 SMEs, the project is focused on foundational knowledge and public health rather than immediate commercial products. However, the massive geographic reach across 18-19 countries provides a high-value global data asset that is rare in private industry.
Contact University College London (UK) regarding the END-VOC data warehouse and AI tools.
Contact SciTransfer to broker access to the END-VOC genomic pipelines for your R&D pipeline.
